Expression of Cripto-1 predicts poor prognosis in stage I non-small cell lung cancer.

Cripto-1 (CR-1) is related to the biological behaviour and prognosis of carcinomas. The purpose of this study was to investigate the significance of CR-1 expression in surgically resected stage I non-small cell lung cancer (NSCLC). One hundred and forty-eight patients with completely resected stage I NSCLC and available clinical follow-up data were assessed. The protein expression of CR-1 in the tumours was detected by immunohistochemistry. CR-1 was highly expressed in 64 of 148 tumours. Among patients with high CR-1 expression, progression-free survival and overall survival rate were significantly lower than those of patients with low CR-1 levels (P = .013 and P = .019, respectively). The incidence of distant metastasis in patients with high CR-1 expression was significantly higher than that of in patients with low CR-1 expression (57.13% vs 21.43%, P = .001). The results of the multivariate analysis confirmed that a high CR-1 was a significant factor for poor prognosis. In conclusion, CR-1 could be a useful prognostic factor in patients with stage I NSCLC, likely as an indicator of the metastatic propensity of the tumour. © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. in both PDF and HTML.

Citation

Chunhua Xu, Qi Yuan, Huidi Hu, Wei Wang, Qian Zhang, Li Li, Jiwang Wang, Rusong Yang. Expression of Cripto-1 predicts poor prognosis in stage I non-small cell lung cancer. Journal of cellular and molecular medicine. 2020 Sep;24(17):9705-9711

Mesh Tags

Substances

PMID: 32697011

search → result